Hereditary angioedema (HAE) is a disease resulting in swelling of one or more parts of the body in the absence of a specific trigger. If the condition occurs in the upper respiratory tract, a so-called HAE attack ensues which can be life threatening. To date, the therapies to treat HAE are in form of injections and infusions. In a Phase 2 study involving the Universitätsklinikum Frankfurt, Charité – Universitätsmedizin Berlin and the Fraunhofer ITMP, it has now been shown for the first time that an orally administered drug can also treat HAE. This therapy has the potential to overcome the issues relating the complicated route of administration for injections as well reduced cost.
more info